Zhang Haoyue, Li Nan, Li Ziping, Li Yize, Yu Yonghao, Zhang Linlin
Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China.
The Graduate School, Tianjin Medical University, Tianjin, China.
Front Pharmacol. 2022 May 3;13:898574. doi: 10.3389/fphar.2022.898574. eCollection 2022.
Chronic pain is a common, complex and unpleasant sensation following nerve injury, tissue trauma, inflammatory diseases, infection and cancer. It affects up to 25% of adults and is increasingly recognized as the leading cause of distress, disability and disease burden globally. Chronic pain is often refractory to most current analgesics, thus emphasizing the requirement for improved therapeutic medications. It is of great importance to elucidate the specific pathogenesis of chronic pain with different etiologies. Recent progress has advanced our understanding in the contribution of neuroinflammation and glial cells (microglia and astrocyte) activation in the plasticity of excitatory nociceptive synapses and the development of chronic pain phenotypes. Oxidative stress-associated neuronal apoptosis is also identified to be a pivotal step for central pain sensitization. The family of cysteine aspartate specific proteases (Caspases) has been well known to be key signaling molecules for inflammation and apoptosis in several neurological conditions. Recent studies have highlighted the unconventional and emerging role of caspases in microgliosis, astrocytes morphogenesis, chemokines release, cytokines secretion and neuronal apoptosis in initiating and maintaining synaptogenesis, synaptic strength and signal transduction in persistent pain hypersensitivity, suggesting the possibility of targeting caspases pathway for prevention and treatment of chronic pain. In this review, we will discuss and summarize the advances in the distinctive properties of caspases family in the pathophysiology of chronic pain, especially in neuropathic pain, inflammatory pain, cancer pain and musculoskeletal pain, with the aim to find the promising therapeutic candidates for the resolution of chronic pain to better manage patients undergoing chronic pain in clinics.
慢性疼痛是神经损伤、组织创伤、炎症性疾病、感染和癌症后常见、复杂且令人不适的感觉。它影响着多达25%的成年人,并且越来越被认为是全球痛苦、残疾和疾病负担的主要原因。慢性疼痛通常对目前大多数镇痛药具有耐药性,因此强调了对改进治疗药物的需求。阐明不同病因慢性疼痛的具体发病机制非常重要。最近的进展加深了我们对神经炎症和胶质细胞(小胶质细胞和星形胶质细胞)激活在兴奋性伤害性突触可塑性和慢性疼痛表型发展中的作用的理解。氧化应激相关的神经元凋亡也被确定为中枢性疼痛敏化的关键步骤。半胱天冬酶家族在几种神经疾病中一直是炎症和凋亡的关键信号分子。最近的研究强调了半胱天冬酶在小胶质细胞增生、星形胶质细胞形态发生、趋化因子释放、细胞因子分泌和神经元凋亡中的非常规和新出现的作用,这些作用在持续性疼痛超敏反应中启动和维持突触形成、突触强度和信号转导,这表明靶向半胱天冬酶途径预防和治疗慢性疼痛的可能性。在这篇综述中,我们将讨论并总结半胱天冬酶家族在慢性疼痛病理生理学,特别是在神经性疼痛、炎性疼痛、癌痛和肌肉骨骼疼痛中的独特性质的研究进展,旨在找到有前景的治疗候选物来缓解慢性疼痛,以便在临床上更好地管理慢性疼痛患者。